1
|
Ai R, Li L, Yuan X, Zhao D, Miao T, Guan W, Dong S, Dong C, Dou Y, Hou M, Nan Y. Identification and validation of plasma AGRN as a novel diagnostic biomarker of hepatitis B Virus-related chronic hepatitis and liver fibrosis/cirrhosis. Histol Histopathol 2024; 39:1025-1035. [PMID: 38197199 DOI: 10.14670/hh-18-695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2024]
Abstract
OBJECTIVE The aim of this study was to find novel biomarkers and develop a non-invasive, effective diagnostic model for hepatitis B Virus-related chronic hepatitis and liver fibrosis/cirrhosis. METHOD Quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to assess the expression of differentially expressed genes (AGRN, JAG1, CCL5, ID3, CCND1, and CAPN2) in peripheral blood mononuclear cells (PBMCs) from healthy subjects, chronic hepatitis B (CHB), and liver fibrosis/cirrhosis (LF/LC) patients. The molecular mechanisms underlying AGRN-regulated CHB were further explored and verified in LX2 cells, in which small interfering RNA (siRNA) was used to block AGRN gene expression. Finally, enzyme-linked Immunosorbent Assay (ELISA) was used to measure AGRN protein expression in 100 healthy volunteers, 100 CHB patients, and 100 LF/LC patients, and the efficacy of the diagnostic model was assessed by the Area Under the Curve (AUC). RESULTS AGRN mRNA displayed a steady rise in the PBMCs of normal, CHB, and LF/LC patients. Besides, AGRN expression was markedly elevated in activated LX2 cells, whereas the expression of COL1 and α-SMA decreased when AGRN was inhibited using siRNA. In addition, downregulation of AGRN can reduce the gene expression of β-catenin and c-MYC while upregulating the expression of GSK-3β. Furthermore, PLT and AGRN were used to develop a non-invasive diagnostic model (PA). To identify CHB patients from healthy subjects, the AUC of the PA model was 0.951, with a sensitivity of 87.0% and a specificity of 91.0%. The AUC of the PA model was 0.922 with a sensitivity of 82.0% and a specificity of 90.0% when differentiating between LF/LC and CHB patients. CONCLUSION The current study indicated that AGRN could be a potential plasma biomarker and the established PA model could improve the diagnostic accuracy for HBV-related liver diseases.
Collapse
Affiliation(s)
- Rong Ai
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Shijiazhuang, China
| | - Lu Li
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Shijiazhuang, China
| | - Xiwei Yuan
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Shijiazhuang, China
| | - Dandan Zhao
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Shijiazhuang, China
| | - Tongguo Miao
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Shijiazhuang, China
| | - Weiwei Guan
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Shijiazhuang, China
| | - Shiming Dong
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Shijiazhuang, China
| | - Chen Dong
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Shijiazhuang, China
| | - Yao Dou
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Shijiazhuang, China
| | - Mengmeng Hou
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Shijiazhuang, China
| | - Yuemin Nan
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, China
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China.
| |
Collapse
|
2
|
Prediction of Type 2 Diabetes at Pre-diabetes Stage by Mass Spectrometry: A Preliminary Study. Int J Pept Res Ther 2022. [DOI: 10.1007/s10989-022-10419-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Zhao D, Yu S, Guo P, Zhang X, Tang Y, Dong C, Zhao S, Li L, Al‐Dhamin Z, Ai R, Xue N, Dong S, Nan Y. Identification of potential plasma markers for hepatitis B virus related chronic hepatitis and liver fibrosis/cirrhosis. J Med Virol 2022; 94:3900-3910. [PMID: 35420168 DOI: 10.1002/jmv.27761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 03/08/2022] [Accepted: 04/02/2022] [Indexed: 11/11/2022]
Affiliation(s)
- Dandan Zhao
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| | - Songhao Yu
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| | - Peilin Guo
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| | - Xiaoxiao Zhang
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| | - Yuhui Tang
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| | - Chen Dong
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| | - Suxian Zhao
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| | - Lu Li
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| | - Zaid Al‐Dhamin
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| | - Rong Ai
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| | - Ningning Xue
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| | - Shiming Dong
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| | - Yuemin Nan
- Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University050051ShijiazhuangChina
- Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver DiseasesChina
| |
Collapse
|
4
|
Kim SW, Choi JW, Yun JW, Chung IS, Cho HC, Song SE, Im SS, Song DK. Proteomics approach to identify serum biomarkers associated with the progression of diabetes in Korean patients with abdominal obesity. PLoS One 2019; 14:e0222032. [PMID: 31504048 PMCID: PMC6736247 DOI: 10.1371/journal.pone.0222032] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Accepted: 08/20/2019] [Indexed: 12/25/2022] Open
Abstract
Type 2 diabetes is a metabolic disease with a group of metabolic derangements and inflammatory reactants in the serum. Despite the substantial public health implications, markers of diabetes progression with abdominal obesity are still needed to facilitate early detection and treatment. In this study, we performed a proteomic approach to identify differential target proteins underlying diabetes progression in patients with abdominal obesity. Proteomic differences were investigated in the serum of controls and patients with prediabetes or diabetes with or without abdominal obesity by 2-DE combined with MALDI-TOF-MS. Proteomics data were validated by western blot analyses and major protein-protein interactions were assessed using a network analysis with String database. Among 245 matched protein spots, 36 exhibited marked differences in normal patients with abdominal obesity, prediabetes, and diabetes compared to levels in normal patients without abdominal obesity. Seven (Alpha-1-antichymotrypsin, Alpha-1-antitrypsin, Apolipoprotein A-I, haptoglobin, retinol-binding protein 4, transthyretin, and zinc-alpha2-glycoprotein) of these spots exhibited significant differences between normal and prediabetes/diabetes patients. After a network analysis, functional annotation using Gene Ontology indicated that most of the identified proteins were involved in lipid transport, lipid localization, and the regulation of serum lipoprotein particle levels. Our results indicated that variation in the levels of these identified protein biomarkers has been reported in normal, prediabetes and diabetic Assessment of the levels of these biomarkers may contribute to the development of biomarkers for not only early diagnosis but also in prognosis of diabetes mellitus type 2.
Collapse
Affiliation(s)
- Sang Woo Kim
- Institute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si, Gangwon-do, South Korea
- Catholic Kwandong University, International St. Mary’s Hospital, Incheon Metropolitan City, South Korea
| | - Jung-Won Choi
- Institute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si, Gangwon-do, South Korea
- Catholic Kwandong University, International St. Mary’s Hospital, Incheon Metropolitan City, South Korea
| | - Jong Won Yun
- Department of Biotechnology, Daegu University, Kyungsan, Kyungbuk, South Korea
| | - In-Sung Chung
- Division of Occupational and Environmental Medicine and Department of Preventive Medicine, Keimyung, University School of Medicine, Daegu, South Korea
| | - Ho Chan Cho
- Department of Internal Medicine, Keimyung, University School of Medicine, Daegu, South Korea
| | - Seung-Eun Song
- Department of Physiology and Obesity-mediated Disease Research Center, Keimyung, University School of Medicine, Daegu, South Korea
| | - Seung-Soon Im
- Department of Physiology and Obesity-mediated Disease Research Center, Keimyung, University School of Medicine, Daegu, South Korea
- * E-mail: (SSI); (DKS)
| | - Dae-Kyu Song
- Department of Physiology and Obesity-mediated Disease Research Center, Keimyung, University School of Medicine, Daegu, South Korea
- * E-mail: (SSI); (DKS)
| |
Collapse
|
5
|
Martins AMA, Garcia JHP, Eberlin MN. Mass Spectrometry as a Clinical Integrative Tool to Evaluate Hepatocellular Carcinoma: Moving to the Mainstream. Expert Rev Gastroenterol Hepatol 2019; 13:821-825. [PMID: 31382786 DOI: 10.1080/17474124.2019.1651643] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Introduction: Since the pioneering work of J. J. Thomson on magnetic deflection of charged particles, mass spectrometry (MS) has become the most progressive clinical tool by continuously providing new applications in medical research. In hepatocellular carcinoma (HCC), MS can be used from surveillance in early stages of the disease to constant evaluation of effective treatments. Areas covered: This Special Report highlights the groundbreaking possibilities of mass spectrometry clinical application in the mainstream to evaluate HCC development and progression. Expert opinon: MS has been employed to understand a myriad of liver diseases, such as the identification of early biomarkers in cirrhosis and HVB and HVC, as well as metabolic alterations of lipidic imbalance in HCC due to fatty liver disease. In an integrative point-of-view, researchers worldwide are looking for molecular signatures that may represent more faithfully the complex scenario of the onset and progression of HCC. Following the steps of MELD score (Model of End-stage Liver Disease), which evaluates biochemical dysfunction of end-stage liver diseases, the necessity to use innovative attempts to pursue a molecular-MEaLD (mMEaLD - molecular Model for Early Liver Disease), shifting MS to the upstream and from the lab facilities into the mainstream, inside the surgery room.
Collapse
Affiliation(s)
- Aline M A Martins
- Translational Medicine Molecular Pathology, Medicine College, Universidade de Brasilia , Brasilia , Brazil.,Department of Surgery, Universidade Federal do Ceara , Fortaleza , Brazil
| | - J Huygens P Garcia
- Department of Surgery, Universidade Federal do Ceara , Fortaleza , Brazil
| | | |
Collapse
|
6
|
Jeong S, Tong Y, Sha M, Gu J, Xia Q. Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget 2017; 8:17292-17300. [PMID: 28030846 PMCID: PMC5370041 DOI: 10.18632/oncotarget.14079] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2016] [Accepted: 12/13/2016] [Indexed: 12/15/2022] Open
Abstract
It has been a decade since hepatitis B virus infection was identified as an etiological factor for the development of intrahepatic cholangiocarcinoma (ICC). In recent years, several studies have elucidated the critical impact of hepatitis B virus in ICC that significantly influenced the clinicopathological characteristics of ICC patients with intrahepatic cholangiocarcinoma. Distinctive features of patients with hepatitis B virus-associated ICC included younger age, preponderance of male patients, frequent elevation of alpha-fetoprotein, and infrequent lymph node metastasis. Furthermore, several studies indicated that the presence of hepatitis B virus is a favorable prognostic factor in terms of overall survival and relapse-free survival. However, there are also a few studies demonstrating that hepatitis B virus negatively influenced or showed no significant association with survival outcomes of patients with ICC. At present, there are no consensus on diagnostic procedures and treatments for such population. Therefore, we elucidated current knowledge and recent identifications of HBV-associated ICC to clarify the impact of chronic HBV infection on patients with ICC and to precisely conduct diagnostic procedures and curative treatments for HBV-associated ICC.
Collapse
Affiliation(s)
- Seogsong Jeong
- Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - Ying Tong
- Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - Meng Sha
- Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - Jinyang Gu
- Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - Qiang Xia
- Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| |
Collapse
|